Nusano News
Nusano and Caspian Studios Announce Launch of Talk Radioisotopes Podcast
Premier episode available today across all podcast platformsVALENCIA, Calif. – Jan. 22, 2025 – Nusano, a physics company transforming the production of radioisotopes,...
Nusano Announces Series C Financing of Over $115M to Commercialize Radioisotopes
Funding supports development and commercialization of broad array of isotopes for medical, commercial and industrial uses VALENCIA, Calif. – Oct. 1, 2024 – Nusano, Inc., a physics company transforming the production of radioisotopes, today announced a Series C...
Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals
Nusano and PharmaLogic announced a supply agreement to provide a more efficient and reliable supply of critical radioisotopes. The agreement will increase access to on-demand radioisotope supplies provided by Nusano for use in pharmaceutical products produced in PharmaLogic’s network of facilities.
Nusano Names D. Scott Holbrook as Chairman of its Board
VALENCIA, Calif. – June 7, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced industry veteran D. Scott Holbrook as chairman of its board. Holbrook is the co-founder of Invivo Molecular Imaging, and currently...
Nusano Expands Executive Management to Support Q1 2025 Radioisotope Commercialization
VALENCIA, Calif. – May 29, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced the addition of three executives to enhance and expand key business process capabilities. These appointments provide additional...
Nusano to Host Radiopharmaceuticals Educational Webinar
EVENT REPLAY NOW AVAILABLE Recorded June 28, 2024Nusano and LifeSci Advisors invite you to go back to school... Join us on Friday, June 28, 2024 from 11:30 a.m. to 12:30 p.m. Eastern for Office Hours: Radiopharmaceuticals. This informative discussion will explain how...
Nusano to Present at Jefferies Radiopharma Innovation Summit
VALENCIA, Calif. – April 10, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced it will attend and present at Jefferies Radiopharma Innovation Summit in New York City on Thursday, April 11, 2024. In his presentation,...
Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress
Nusano will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile. Greg Moffitt, Nusano Director of Target Development, will provide an overview of the company’s proprietary radioisotope production platform on Sunday, March 24.
Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration
Photo above: On Friday, March 8, 2024, representatives from Nusano and The Wasatch Group cut the ribbon on the Radiance Lab, a 5,000 square foot radiochemistry space that will develop radioisotope separation and purification processes for Nusano. (L-to-R) Howard...
Nusano to Participate in the B. Riley Securities Radiopharma Investor Conference
VALENCIA, Calif. – February 26, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced it will participate in a presentation and panel at the B. Riley Securities Radiopharma Investor Conference in New York City on...
Nusano Names Rohan Jain as Commercial General Manager
VALENCIA, Calif. – Jan. 22, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced Rohan Jain as its Commercial General Manager. Jain and his team will work with Nusano’s customers and prospects to assess their needs and...
BLOG Posts
MedicalXpress: Researchers develop new method of precisely targeting cancer lesions while protecting healthy tissues
From MedicalXpress: A team of researchers has developed a new method that suppresses the distribution of drugs to...
ICR: ‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer
News from the United Kingdom's Institute of Cancer Research (ICR) published in The Lancet Oncology reports that...
Case Study: Radioisotope supply challenges affecting prostate cancer treatment
Experts at the Dana-Farber Cancer Institute report patient treatments were delayed by three months due to low supply of 177Lu-PSMA-617.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates